The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC

被引：0
|
作者：
Sarina, Piha-Paul
Xu, Binghe
Fan, Ying
Yuan, Yuan
Lavasani, Sayeh
Mortimer, Joanne
Goel, Sanjay
Tsimberidou, Apostolia
Ibrahim, Nuhad
Abouharb, Sausan
Barcenas, Carlos
Lheme, Adaeze
Karp, Daniel
Ahnert, Jordi Rodon
Dumbrava, Ecaterina
Fan, Jean
Peng, Peng
Sun, Caixia
Wang, Hui
Hennessy, Katie
Fu, Ximei
Xu, Ruolan
Ni, Shumao
Wu, Frank
Meric-Bernstam, Funda
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-RF01-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
RF01-07
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Efficacy of chemotherapy in patients with HR+/HER2-Invasive lobular breast cancer
    Yaghi, Marita
    Bilani, Nadeem
    Dominguez, Barbara
    Zerdan, Maroun Bou
    Li, Hong
    Saravia, Diana
    Stone, Elizabeth
    Nahleh, Zeina
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 34
  • [42] Therapy of advanced HR+, HER2-Breast Cancer Live professionally longer with CDK4/6 Inhibitor
    Ruedesheim, Sabine M.
    BREAST CARE, 2021, 16 (03)
  • [43] BUDGET IMPACT ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Velchev, M.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [44] Palbociclib Fails to Prevent Recurrence After Neoadjuvant Therapy in HR+/HER2-Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S7 - S8
  • [45] Ribociclib for post-menopausal women with HR+/HER2-advanced or metastatic breast cancer
    Zangardi, Mark L.
    Spring, Laura M.
    Blouin, Gayle C.
    Bardia, Aditya
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1169 - 1176
  • [46] Advancing Treatment and Management of Patients with HR+/HER2-Breast Cancer: Findings from a Quality Improvement Initiative
    Meisel, Jane
    Anderson, Chelsie
    Dewald, Ilona
    Carter, Jeffrey
    Heggen, Cherilyn
    McKinnon, Kelly
    CANCER RESEARCH, 2024, 84 (09)
  • [47] WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN WOMEN WITH HR+/HER2-ADVANCED/ METASTATIC BREAST CANCER
    Wood, R.
    Mitra, D.
    DeCourcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2017, 20 (05) : A123 - A123
  • [48] Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer
    Fasching, P. A.
    Fernandez Abad, M.
    Garcia-Saenz, J. A.
    Schneeweiss, A.
    Guarneri, V.
    Colleoni, M.
    Petru, E.
    Costigan, T. M.
    Caldwell, C. W.
    Barriga, S.
    Hurvitz, S.
    Slamon, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 225 - +
  • [49] Therapeutic evolution in HR+/HER2-breast cancer: from targeted therapy to endocrine therapy
    Cao, Lu-Qi
    Sun, Haidong
    Xie, Yuhao
    Patel, Harsh
    Bo, Letao
    Lin, Hanli
    Chen, Zhe-Sheng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [50] The transcription factor CBFB mutations indicate an improved survival in HR+/HER2-breast cancer
    Guo, Liping
    Chen, Bo
    Zhang, Guochun
    Wang, Yulei
    Cao, Li
    Ren, Chongyang
    Wen, Lingzhu
    Lin, Jiali
    Wei, Guangnan
    Liao, Ning
    GENE, 2020, 759
12345